Fundraising Fox

Melinta Therapeutics INC /New

New Haven, US · Delaware corporation

Biotech

Founders & leadership

SC
Sue CammarataExecutive Vice President and Chief Medical Officer
DW
Daniel WechslerDirector, President and Chief Executive Officer
ED
Erin DuffyExecutive Vice President and Chief Scientific Officer
PE
Paul EstremExecutive

Board

GK
Garheng KongBoard director
KT
Kevin T. FerroChairman of the Board
TP
Thomas P. KoestlerBoard director
CG
Cecilia GonzaloBoard director
JH
John H. JohnsonBoard director
DG
David GillBoard director
DZ
David ZaccardelliBoard director
JJ
Jay J. Galeota, Jr.Board director

Reported raises · per SEC filings

Form D private placements

$270.7M disclosed across 2 rounds · 2017–2018

▶$137.8MraisedJan 2018 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John H. JohnsonDirector
  • David GillDirector
  • Garheng KongDirector
  • David ZaccardelliDirector
  • Sue CammarataExecutive Officer
  • Kevin T. FerroDirector
  • Thomas P. KoestlerDirector
  • Jay J. Galeota, Jr.Director
  • Daniel WechslerExecutive Officer, Director
  • Cecilia GonzaloDirector
  • Erin DuffyExecutive Officer
  • Paul EstremExecutive Officer
Offering amount
$137.8M
Amount sold
$137.8M
First sale
Jan 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$132.9MraisedNov 2017 · 39 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David ZaccardelliDirector
  • Cecilia GonzaloDirector
  • David GillDirector
  • Jay GaleotaDirector
  • Sue CammarataExecutive Officer
  • Garheng KongDirector
  • John JohnsonDirector
  • Thomas P. KoestlerDirector
  • Daniel WechslerExecutive Officer, Director
  • Erin DuffyExecutive Officer
  • John TemperatoExecutive Officer
  • Paul EstremExecutive Officer
  • Kevin FerroDirector
Offering amount
$132.9M
Amount sold
$132.9M
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

How much funding has Melinta Therapeutics INC /New raised?
Melinta Therapeutics INC /New has disclosed $270.7M raised across 2 rounds.
Where is Melinta Therapeutics INC /New headquartered?
Melinta Therapeutics INC /New is headquartered in New Haven, US.